Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, Alexandra M Poos, Andriy Derkach, Kylee Maclachlan, Michael Durante, Benjamin Diamond, Marios Papadimitriou, Faith Davies, Eileen M Boyle, Brian Walker, Malin Hultcrantz, Ariosto Silva, Oliver Hampton, Jamie K Teer, Erin M Siegel, Niccolò Bolli, Graham H Jackson, Martin Kaiser, Charlotte Pawlyn, Gordon Cook, Dickran Kazandjian, Caleb Stein, Marta Chesi, Leif Bergsagel, Elias K Mai, Hartmut Goldschmidt, Katja C Weisel, Roland Fenk, Marc S Raab, Fritz Van Rhee, Saad Usmani, Kenneth H Shain, Niels Weinhold, Gareth Morgan, Ola Landgren
PURPOSE: Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS: To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS: Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression-based molecular classifications...
January 9, 2024: Journal of Clinical Oncology